BRPI0919020B8 - use of enriched monocyte lineage cells to treat ischemia and to treat angina pectoris - Google Patents
use of enriched monocyte lineage cells to treat ischemia and to treat angina pectorisInfo
- Publication number
- BRPI0919020B8 BRPI0919020B8 BRPI0919020A BRPI0919020A BRPI0919020B8 BR PI0919020 B8 BRPI0919020 B8 BR PI0919020B8 BR PI0919020 A BRPI0919020 A BR PI0919020A BR PI0919020 A BRPI0919020 A BR PI0919020A BR PI0919020 B8 BRPI0919020 B8 BR PI0919020B8
- Authority
- BR
- Brazil
- Prior art keywords
- treat
- ischemia
- angina pectoris
- lineage cells
- monocyte lineage
- Prior art date
Links
- 206010002383 Angina Pectoris Diseases 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 title abstract 3
- 210000001616 monocyte Anatomy 0.000 title abstract 3
- 208000028867 ischemia Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000004700 fetal blood Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 201000002818 limb ischemia Diseases 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- -1 umbilical cord blood Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
Abstract
uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris. a presente invenção refere-se a composições e métodos para o tratamento de doenças e condições isquêmicas, particularmente isquemia do miocárdio, do snc/cérebro e de membros. mais particularmente, a presente invenção estabelece métodos de tratamento de doenças mediante administração de monócitos obtidos de sangue, incluindo sangue de cordão umbilical, sangue periférico ou medula óssea, a um indivíduo que precisa de tratamento, em que a formulação específica é administrada para o indivíduo, em um tempo especificamente determinado para proporcionar a eficácia terapêutica. em uma modalidade, as células são para injeção no miocárdio isquêmico para o tratamento de angina.use of enriched monocyte lineage cells to treat ischemia and to treat angina pectoris. The present invention relates to compositions and methods for treating ischemic diseases and conditions, particularly myocardial, snc/brain and limb ischemia. more particularly, the present invention provides methods of treating diseases by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood or bone marrow, to an individual in need of treatment, wherein the specific formulation is administered to the individual. , at a time specifically determined to provide therapeutic efficacy. in one embodiment, the cells are for injection into the ischemic myocardium for the treatment of angina.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9672708P | 2008-09-12 | 2008-09-12 | |
US61/096,727 | 2008-09-12 | ||
US17380709P | 2009-04-29 | 2009-04-29 | |
US61/173,807 | 2009-04-29 | ||
PCT/US2009/056867 WO2010031006A1 (en) | 2008-09-12 | 2009-09-14 | Ischemic tissue cell therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0919020A8 BRPI0919020A8 (en) | 2018-05-29 |
BRPI0919020B1 BRPI0919020B1 (en) | 2021-03-23 |
BRPI0919020B8 true BRPI0919020B8 (en) | 2021-05-25 |
Family
ID=42005531
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0919020D BRPI0919020A2 (en) | 2008-09-12 | 2009-09-14 | USE OF ENRICHED MONOCYTE LINE CELLS TO TREAT ISCHEMIA AND TO TREAT ANGINA PECTORIS |
BRPI0919020A BRPI0919020B8 (en) | 2008-09-12 | 2009-09-14 | use of enriched monocyte lineage cells to treat ischemia and to treat angina pectoris |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0919020D BRPI0919020A2 (en) | 2008-09-12 | 2009-09-14 | USE OF ENRICHED MONOCYTE LINE CELLS TO TREAT ISCHEMIA AND TO TREAT ANGINA PECTORIS |
Country Status (9)
Country | Link |
---|---|
US (2) | US8784802B2 (en) |
EP (1) | EP2331679B1 (en) |
JP (4) | JP6105846B2 (en) |
CN (2) | CN102186970A (en) |
BR (2) | BRPI0919020A2 (en) |
CA (1) | CA2737193A1 (en) |
HK (1) | HK1248125A1 (en) |
RU (1) | RU2535966C2 (en) |
WO (1) | WO2010031006A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011121036A2 (en) | 2010-03-30 | 2011-10-06 | Vib Vzw | Induction of arteriogenesis using specific factors or by cell therapy with polarized myeloid cells |
EP2412724A1 (en) * | 2010-07-29 | 2012-02-01 | Centre National de la Recherche Scientifique (C.N.R.S) | Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof |
CN101940594B (en) * | 2010-08-27 | 2013-12-04 | 上海士腾生物技术有限公司 | Preparation for treating ischemic cardiovascular diseases and preparation method thereof |
EP2776057B1 (en) * | 2011-11-07 | 2020-04-15 | Hina W. Chaudhry | A population of cells comprising placenta-derived cells which express cdx2 for use in treatment of damaged or degenerated heart tissue by inducing cardiac regeneration |
ITPD20120318A1 (en) * | 2012-10-29 | 2014-04-30 | Alvaro Bido | REFRIGERANT LIQUID |
US20160287638A1 (en) * | 2015-04-02 | 2016-10-06 | Stemedica Cell Technologies, Inc. | Ischemic tolerant cells and cellular factors in the treatment of peripheral artery disease |
RU2017139781A (en) * | 2015-04-21 | 2019-05-21 | Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния | SYSTEM AND METHOD FOR CONTROL AND TREATMENT OF ARRHYTHM AND CARDIAC FUNCTION THROUGH THE INTERNAL HEART NERVOUS SYSTEM |
JP6903866B2 (en) * | 2016-01-27 | 2021-07-14 | 国立大学法人 熊本大学 | Method for inducing proliferation of blood-derived monocytes |
AU2017315174B2 (en) * | 2016-08-26 | 2023-11-09 | Fundación Pública Andaluza Progreso Y Salud | Cell suspension for use in the treatment of lower extremity peripheral artery disease |
BR112019016672A8 (en) | 2017-02-13 | 2022-11-08 | Hopitaux Paris Assist Publique | METHOD TO GENERATE T CELL PROGENITORS |
US20200155607A1 (en) * | 2017-04-25 | 2020-05-21 | Abraham J And Phyllis Katz Cord Blood Foundation | Enriched Cellular Compositions and Therapeutic Use |
RU2661048C1 (en) * | 2017-12-28 | 2018-07-11 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Method of treatment of patients with acute myocardial infarction with late hospitalization |
JP7466547B2 (en) | 2019-08-09 | 2024-04-12 | 公益財団法人神戸医療産業都市推進機構 | Screening method for vascular endothelial cell activator |
RU2725860C1 (en) * | 2019-12-26 | 2020-07-06 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский университет "Московский институт электронной техники" | Tissue engineering structure for cardiac tissue regeneration |
US20220202860A1 (en) * | 2020-12-30 | 2022-06-30 | Creative Medical Technologies, Inc. | Treatment of heart failure and/or post infarct pathological remodeling by ex vivo reprogrammed immune cells |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
NL154599B (en) | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (en) | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
GB9310557D0 (en) | 1993-05-21 | 1993-07-07 | Smithkline Beecham Plc | Novel process and apparatus |
US5908782A (en) | 1995-06-05 | 1999-06-01 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
US5800812A (en) * | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
US6267955B1 (en) * | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
EP1028737B1 (en) | 1997-07-03 | 2007-04-04 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells from peripheral blood |
AU2001261737A1 (en) * | 2000-05-18 | 2001-11-26 | Genetix Pharmaceuticals, Inc. | Methods and compositions for promoting angiogenesis using monocytes |
JP2002069001A (en) * | 2000-08-29 | 2002-03-08 | Asahi Kasei Corp | Cell vaccine consisting mainly of dendritic cell |
JP2002171965A (en) * | 2000-12-04 | 2002-06-18 | Kansai Tlo Kk | Method of separating and concentrating bone marrow monocyte cells and revascularizing agent |
US20050202098A1 (en) * | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
US8377692B2 (en) * | 2001-11-21 | 2013-02-19 | Yeda Research And Development Co., Ltd. | Process for the manufacturing of human mononuclear phagocytic leukocytes |
WO2004010959A2 (en) * | 2002-07-25 | 2004-02-05 | The Scripps Research Institute | Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith |
US9969977B2 (en) | 2002-09-20 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
JP2007502805A (en) * | 2003-08-18 | 2007-02-15 | ビーティージー・インターナショナル・リミテッド | Treatment of neurodegenerative conditions |
JP2006050976A (en) * | 2004-08-12 | 2006-02-23 | Asahi Kasei Medical Co Ltd | Method for recovering cell |
CN1754574A (en) * | 2004-09-27 | 2006-04-05 | 深圳市中兴扬帆生物工程有限公司 | Use of immune cell for treating blood coloboma symptom and arrest of bone marrow |
WO2006047593A2 (en) * | 2004-10-22 | 2006-05-04 | University Of South Florida | Method of potentiating inflammatory and immune modulation for cell and drug therapy |
US20070231306A1 (en) * | 2005-02-24 | 2007-10-04 | The Scripps Research Institute | Isolated myeloid-like cell populations and methods of treatment therewith |
JP4949230B2 (en) * | 2005-03-03 | 2012-06-06 | 株式会社カネカ | Cell preparation method and apparatus |
US20060210543A1 (en) * | 2005-03-21 | 2006-09-21 | Jonathan Leor | Method of treating infarcted myocardium |
PL1951864T3 (en) | 2005-11-07 | 2014-10-31 | Pecora & Co Llc | Compositions and methods of vascular injury repair |
US7833789B2 (en) * | 2006-08-01 | 2010-11-16 | Fondazione Centro San Raffaele Del Monte Tabor | Monocyte cell |
US20080206196A1 (en) * | 2007-02-26 | 2008-08-28 | Calvin Cao | Differentiation of cord blood into neural like cells, and method to treat neurological condition patients |
-
2009
- 2009-09-14 RU RU2011113869/10A patent/RU2535966C2/en not_active IP Right Cessation
- 2009-09-14 BR BRPI0919020D patent/BRPI0919020A2/en unknown
- 2009-09-14 CN CN200980139421XA patent/CN102186970A/en active Pending
- 2009-09-14 CN CN201710060312.5A patent/CN107595889A/en active Pending
- 2009-09-14 US US13/063,456 patent/US8784802B2/en active Active
- 2009-09-14 EP EP09813763.1A patent/EP2331679B1/en not_active Not-in-force
- 2009-09-14 WO PCT/US2009/056867 patent/WO2010031006A1/en active Application Filing
- 2009-09-14 JP JP2011527030A patent/JP6105846B2/en not_active Expired - Fee Related
- 2009-09-14 CA CA2737193A patent/CA2737193A1/en not_active Abandoned
- 2009-09-14 BR BRPI0919020A patent/BRPI0919020B8/en active IP Right Grant
-
2014
- 2014-02-17 JP JP2014027268A patent/JP2014088443A/en not_active Withdrawn
- 2014-07-21 US US14/336,621 patent/US10335434B2/en active Active
-
2016
- 2016-04-11 JP JP2016078709A patent/JP2016128521A/en active Pending
-
2017
- 2017-09-08 JP JP2017173071A patent/JP2017214426A/en not_active Withdrawn
-
2018
- 2018-06-14 HK HK18107708.8A patent/HK1248125A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0919020B1 (en) | 2021-03-23 |
JP2014088443A (en) | 2014-05-15 |
US20110274674A1 (en) | 2011-11-10 |
EP2331679A1 (en) | 2011-06-15 |
RU2535966C2 (en) | 2014-12-20 |
WO2010031006A1 (en) | 2010-03-18 |
HK1248125A1 (en) | 2018-10-12 |
CN107595889A (en) | 2018-01-19 |
US8784802B2 (en) | 2014-07-22 |
CA2737193A1 (en) | 2010-03-18 |
JP2016128521A (en) | 2016-07-14 |
US20140369983A1 (en) | 2014-12-18 |
JP2017214426A (en) | 2017-12-07 |
CN102186970A (en) | 2011-09-14 |
EP2331679A4 (en) | 2012-12-26 |
JP6105846B2 (en) | 2017-03-29 |
EP2331679B1 (en) | 2017-04-19 |
JP2012502114A (en) | 2012-01-26 |
BRPI0919020A8 (en) | 2018-05-29 |
US10335434B2 (en) | 2019-07-02 |
RU2011113869A (en) | 2012-10-20 |
BRPI0919020A2 (en) | 2017-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0919020B8 (en) | use of enriched monocyte lineage cells to treat ischemia and to treat angina pectoris | |
BR112016014481A2 (en) | cancer treatment using combinations of erk and raf inhibitors | |
EA201500265A1 (en) | ANTI-FLY VIRUS REPLICATION INHIBITORS | |
BR112015006828A8 (en) | compound, or a pharmaceutically acceptable salt thereof; pharmaceutical composition; use of the compound; and method for modulating the activity of an ire1 protein | |
BR112014000240A2 (en) | benzylamine derivatives as inhibitors of plasma kallikrein | |
AR044007A1 (en) | METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
BR112012029959A2 (en) | Mentyl carbamate compounds as skin and / or hair lightening actives | |
BR112015028879A8 (en) | heterocyclic derivative compounds, pharmaceutical composition comprising said compounds and uses thereof | |
BR112012031163A2 (en) | Combination therapy methods for treatment of proliferative diseases | |
MX2021009652A (en) | Nicotinamide riboside compositions for topical use in treating skin conditions. | |
BR112012018500A2 (en) | some quinurenine-3-monooxygenase inhibitors, pharmaceutical compositions and methods of use thereof | |
BR112014010291A2 (en) | combinatorial liposome compositions for cancer therapy | |
CO7101246A2 (en) | Carbamate compound and preparation and use thereof | |
AR067903A1 (en) | METHOD TO TREAT STRESSED DEPRESSION | |
BR112016013734A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, KIT, AND USE OF A COMPOUND | |
SV2011003901A (en) | ARILO COMPOUNDS WITH HETEROCYCLIC SUBSTITUTES AS HIF INHIBITORS | |
BR112013027119A8 (en) | new ligand-drug conjugates (adcs) and their use | |
BR112012023421A2 (en) | pharmaceutical composition for intraocular pressure increase treatment | |
CU20070203A7 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A DIFFENILUREA REPLACED WITH OMEGA-CARBOXIARIL FOR THE TREATMENT OF CANCER | |
WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
AR096892A1 (en) | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | |
BR112014003071A2 (en) | treatment of peripheral vascular disease using umbilical cord tissue derived cells | |
EP3818991A3 (en) | Compositions and methods for treating diseases | |
BRPI0518000A (en) | aryl- and heteroaryl-substituted tetrahydroisoquinolines and their use to block reabsorption of norepinephrine, dopamine and serotonin | |
BR112013020586A2 (en) | USE OF UMBILICAL CORD TISSUE DERIVED CELLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: CRYOPRAXIS CRIOBIOLOGIA LTDA (BR/RJ) , UNIVERSITY |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |